Objectives: To estimate the prevalence of fibromyalgia (FM) and chronic widespread pain (CWP) in community-dwelling elderly individuals living in São Paulo, to assess the spectrum of problems related to these diseases using the Fibromyalgia Impact Questionnaire (FIQ) and to correlate the FIQ with the number of tender points and with pain threshold.
Methods: Our sample consisted of 361 individuals (64% women, 36% men, mean age of 73.3±5.7 years). Individuals were classified into four groups: FM (according to American College of Rheumatology criteria), CWP, regional pain (RP) and no pain (NP). Pain characteristics and dolorimetry for 18 tender points and the FIQ were assessed.
Results: The prevalence of FM was 5.5% [95% confidence interval (CI)=5.4-5.7], and the prevalence of CWP was 14.1% (95% CI: 10.5-17.7%). The frequency of RP was 52.6% and the prevalence of NP was 27.7%. FIQ scores were higher in people with FM (44.5), followed by CWP (31.4), RP (18.1) and NP (5.5) (p<0.001). There was a positive correlation between the domains of the FIQ and the number of tender points (p<0.05), and a negative correlation between FIQ score and pain threshold (p<0.05).
Conclusion: In our elderly subjects, the prevalence of FM was slightly higher compared to previously reported studies, and CWP was around 14%. The spectrum of problems related to chronic pain was more severe in FM followed by CWP, strongly suggesting that these conditions should be diagnosed and adequately treated in older individuals.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.maturitas.2010.07.006 | DOI Listing |
Cureus
November 2024
Orthopedics, Jawaharlal Nehru Medical College and Hospital, Bhagalpur, IND.
Introduction Arthritis affects a significant number of adults in the United States, leading to pain and limited mobility. This study explores the impact of physical activity on patients with arthritis, including rheumatoid arthritis, gout, lupus, and fibromyalgia. Using data from the Behavioral Risk Factor Surveillance System (BRFSS), it examines how exercise may improve symptoms and quality of life for these patients.
View Article and Find Full Text PDFRMD Open
December 2024
Rheumatology, Hopital Cochin, Université Paris Descartes Faculté de Médecine, Paris, France.
Introduction: The study aimed to identify and describe disease activity trajectories over 10 years in patients with recent-onset axial spondyloarthritis (axSpA) and determine their impact on long-term outcomes.
Methods: This prospective, multicentre study (Devenir des Spondylarthropathies Indifférenciées Récentes cohort, ClinicalTrials.gov NCT) followed patients with early axSpA for 10 years.
Adv Rheumatol
December 2024
Department of Internal Medicine, Federal University of Paraiba, João Pessoa, Paraiba, 58050-085, Brazil.
Introduction: The prevalence of Fibromyalgia in patients with Systemic Lupus Erythematosus (SLE) is significantly higher compared to the general population. Despite this frequent association, Fibromyalgia remains underdiagnosed and consequently inadequately treated, negatively affecting the quality of life of these patients.
Objective: This study aims to evaluate the occurrence of Fibromyalgia and its impact on the quality of life of Brazilian patients with SLE treated at a University Hospital in the state of Paraiba.
Mol Biol Rep
December 2024
Department of Physiology, Faculty of Medicine, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Fibromyalgia (FM) is a complex, chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, and cognitive disturbances. Despite its prevalence, the pathophysiology of FM remains poorly understood, with current treatments often providing limited relief. Recent studies have suggested that metformin, a widely used antidiabetic drug, may have potential therapeutic benefits for chronic pain conditions, including FM.
View Article and Find Full Text PDFElectrophoresis
December 2024
Unit of Forensic Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Pregabalin (PGB) is a novel gamma-aminobutyric acid analog that has been recently approved for the treatment of partial-onset seizures, neuropathic pain, and fibromyalgia. Although PGB presents a low potential for abuse in comparison to other scheduled drugs, the literature reports its potential misuse, especially among individuals with former or current drug addiction. The present study aimed to develop and validate a novel method for the determination of PGB in hair to perform a retrospective observational study on the misuse of this drug in a population of addicted subjects from Northern Algeria.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!